

# Aryeh Fischer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8150492/publications.pdf>

Version: 2024-02-01

84  
papers

8,479  
citations

87723

38  
h-index

74018

75  
g-index

88  
all docs

88  
docs citations

88  
times ranked

4944  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nintedanib for Systemic Sclerosis-associated Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2019, 380, 2518-2528.	13.9	1,025
2	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2015, 46, 976-987.	3.1	803
3	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	5.2	754
4	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 147-157.	5.2	410
5	Rheumatoid Arthritis-associated Interstitial Lung Disease-associated Mortality. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 372-378.	2.5	389
6	Interstitial lung disease in connective tissue disorders. <i>Lancet</i> , 2012, 380, 689-698.	6.3	338
7	Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , 2013, 40, 640-646.	1.0	316
8	Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. <i>European Respiratory Journal</i> , 2016, 47, 588-596.	3.1	277
9	Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Chest</i> , 2010, 138, 251-256.	0.4	275
10	Scleroderma lung disease. <i>European Respiratory Review</i> , 2013, 22, 6-19.	3.0	230
11	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , 2016, 43, 1672-1679.	1.0	222
12	Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients With Connective Tissue Disease-Related Interstitial Lung Disease. <i>Chest</i> , 2006, 130, 30-36.	0.4	221
13	Characterisation of patients with interstitial pneumonia with autoimmune features. <i>European Respiratory Journal</i> , 2016, 47, 1767-1775.	3.1	219
14	Fibrosing interstitial lung diseases: knowns and unknowns. <i>European Respiratory Review</i> , 2019, 28, 180100.	3.0	191
15	Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. <i>Respiratory Medicine</i> , 2012, 106, 1040-1047.	1.3	175
16	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. <i>Current Medical Research and Opinion</i> , 2019, 35, 2015-2024.	0.9	148
17	Update in the Diagnosis and Management of Pulmonary Vasculitis. <i>Chest</i> , 2006, 129, 452-465.	0.4	138
18	Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. <i>Respiratory Medicine</i> , 2009, 103, 1719-1724.	1.3	138

#	ARTICLE	IF	CITATIONS
19	Clinically Significant Interstitial Lung Disease in Limited Scleroderma. <i>Chest</i> , 2008, 134, 601-605.	0.4	136
20	Rheumatoid Arthritis-Associated Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality. <i>Journal of Rheumatology</i> , 2019, 46, 360-369.	1.0	130
21	Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). <i>Respiratory Medicine</i> , 2013, 107, 1247-1252.	1.3	115
22	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. <i>Respiratory Medicine</i> , 2016, 119, 150-154.	1.3	111
23	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , 2014, 69, 436-444.	2.7	100
24	Unique Characteristics of Systemic Sclerosis Sine Scleroderma-Associated Interstitial Lung Disease. <i>Chest</i> , 2006, 130, 976-981.	0.4	90
25	Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2009, 136, 841-848.	0.4	90
26	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. <i>Mayo Clinic Proceedings</i> , 2019, 94, 309-325.	1.4	78
27	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	1.6	69
28	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. <i>Chest</i> , 2014, 145, 454-463.	0.4	67
29	Interstitial Pneumonia with Autoimmune Features. <i>Annals of the American Thoracic Society</i> , 2019, 16, 525-533.	1.5	62
30	Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. <i>Respiratory Medicine</i> , 2010, 104, 1350-1355.	1.3	60
31	Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. <i>Journal of Rheumatology</i> , 2006, 33, 1600-5.	1.0	58
32	Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 392-400.	1.3	49
33	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. <i>BMJ Open Respiratory Research</i> , 2018, 5, e000289.	1.2	48
34	Minor Salivary Gland Biopsy To Detect Primary Sjögren Syndrome in Patients With Interstitial Lung Disease. <i>Chest</i> , 2009, 136, 1072-1078.	0.4	47
35	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. <i>European Respiratory Review</i> , 2018, 27, 170139.	3.0	47
36	Pericardial Abnormalities Predict the Presence of Echocardiographically Defined Pulmonary Arterial Hypertension in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Chest</i> , 2007, 131, 988-992.	0.4	45

#	ARTICLE	IF	CITATIONS
37	Connective Tissue Disease-associated Lung Disease. <i>Immunology and Allergy Clinics of North America</i> , 2012, 32, 513-536.	0.7	40
38	Humanistic and cost burden of systemic sclerosis: A review of the literature. <i>Autoimmunity Reviews</i> , 2017, 16, 1147-1154.	2.5	39
39	Update on morbidity and mortality in systemic sclerosis-related interstitial lung disease. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 11-20.	1.0	39
40	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. <i>Respiration</i> , 2015, 90, 177-184.	1.2	38
41	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. <i>Clinical Rheumatology</i> , 2019, 38, 2673-2681.	1.0	38
42	Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2017, 127, 1-6.	1.3	37
43	The lung may play a role in the pathogenesis of rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 295-309.	0.3	36
44	A Multidisciplinary Evaluation Helps Identify the Antisynthetase Syndrome in Patients Presenting as Idiopathic Interstitial Pneumonia. <i>Journal of Rheumatology</i> , 2016, 43, 887-892.	1.0	30
45	Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD). <i>Current Respiratory Medicine Reviews</i> , 2015, 11, 175-183.	0.1	30
46	All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. <i>Journal of Rheumatology</i> , 2018, 45, 235-241.	1.0	29
47	Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 159-165.	0.8	28
48	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial. <i>Respiratory Medicine</i> , 2016, 117, 254-263.	1.3	26
49	Current approach to connective tissue disease-associated interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 449-456.	1.2	24
50	Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis. <i>Advances in Therapy</i> , 2019, 36, 1100-1113.	1.3	23
51	Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. <i>Open Access Rheumatology: Research and Reviews</i> , 2019, Volume 11, 283-307.	0.8	23
52	Recent advances in connective tissue disease related interstitial lung disease. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 591-603.	1.0	21
53	Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e482-e490.	0.5	21
54	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA <sub>1</sub> ) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001026.	1.2	20

#	ARTICLE	IF	CITATIONS
55	Assessment and management of connective tissue disease-associated interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32, 2-21.	0.2	19
56	Recent onset systemic lupus erythematosus complicated by acute respiratory failure. Arthritis Care and Research, 2013, 65, 314-323.	1.5	18
57	Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 2019, 197, 709-713.	1.4	18
58	Primary care assessment of capillaroscopy abnormalities in patients with Raynaud's phenomenon. Clinical Rheumatology, 2015, 34, 2135-2140.	1.0	16
59	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	1.3	16
60	Radiologic vignette: Hughes-Stovin syndrome. Arthritis and Rheumatism, 2005, 53, 114-116.	6.7	15
61	Management of Connective Tissue Disease-associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 279-294.	0.8	14
62	Interstitial Lung Disease. Journal of Clinical Rheumatology, 2009, 15, 95-99.	0.5	12
63	Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. Journal of Rheumatology, 2019, 46, 920-927.	1.0	12
64	Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinical Pulmonary Medicine, 2009, 16, 74-80.	0.3	10
65	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. European Respiratory Journal, 2016, 47, 1295-1296.	3.1	10
66	Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged. Respiratory Medicine, 2017, 132, 267.	1.3	9
67	Connective Tissue Disease-related Thoracic Disease. Clinics in Chest Medicine, 2015, 36, 283-297.	0.8	8
68	Interstitial Lung Abnormalities in Rheumatoid Arthritis Are Common and Important. Chest, 2014, 146, 8-10.	0.4	7
69	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 106-113.	0.4	7
70	Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 475-476.	0.2	5
71	Interstitial Pneumonia with Autoimmune Features. Clinics in Chest Medicine, 2019, 40, 609-616.	0.8	5
72	POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest, 2019, 155, 258-260.	0.4	5

#	ARTICLE	IF	CITATIONS
73	Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. American Journal of Medicine, 2019, 132, e854-e855.	0.6	1
74	Interstitial Pneumonia With Autoimmune Features. , 2022, , 298-306.		1
75	Response. Chest, 2007, 131, 940-941.	0.4	0
76	Reply to Wallis from Iseman and Fischer. Clinical Infectious Diseases, 2008, 47, 1605-1605.	2.9	0
77	Demystifying Lung Disease in the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2015, 41, xiii-xiv.	0.8	0
78	P100 &lt;br /&gt; Understanding the Determinants of Health-Related Quality of Life in Rheumatoid Arthritis-Associated Interstitial Lung Disease. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.2	0
79	Rebuttal From Drs Lee and Fischer. Chest, 2019, 155, 263-264.	0.4	0
80	OP0242&#x2013;SAFETY PROFILE OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE AND IDIOPATHIC PULMONARY FIBROSIS. , 2019, , .		0
81	OP0017&#x2013;NINTEDANIB REDUCED DECLINE IN FORCED VITAL CAPACITY ACROSS SUBGROUPLIPS OF PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE: DATA FROM THE SENSISCIS TRIAL. , 2019, , .		0
82	FRI0301&#x2013;GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSISCIS TRIAL. , 2019, , .		0
83	It takes a village to care for the patient with idiopathic pulmonary fibrosis. Cleveland Clinic Journal of Medicine, 2018, 85, 387-389.	0.6	0
84	Interstitial pneumonia with autoimmune features. , 2019, , 140-152.		0